S
SAVARA INC
NASDAQ: SVRA (Savara, Inc.)
Last update: 6 hours ago5.12
-0.12 (-2.29%)
| Previous Close | 5.24 |
| Open | 5.19 |
| Volume | 1,117,036 |
| Avg. Volume (3M) | 1,610,132 |
| Market Cap | 1,049,201,344 |
| Price / Book | 4.89 |
| 52 Weeks Range | |
| Earnings Date | 13 May 2026 |
| Diluted EPS (TTM) | -0.490 |
| Total Debt/Equity (MRQ) | 20.08% |
| Current Ratio (MRQ) | 14.91 |
| Operating Cash Flow (TTM) | -95.63 M |
| Levered Free Cash Flow (TTM) | -56.02 M |
| Return on Assets (TTM) | -38.97% |
| Return on Equity (TTM) | -75.77% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Savara, Inc. | Mixed | Bullish |
AIStockmoo Score
1.1
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | 1.13 |
|
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 5.38% |
| % Held by Institutions | 98.53% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Nea Management Company, Llc | 31 Dec 2025 | 24,471,264 |
| Bain Capital Life Sciences Investors, Llc | 31 Dec 2025 | 17,600,621 |
| Vr Adviser, Llc | 31 Dec 2025 | 13,740,375 |
| Polar Capital Holdings Plc | 31 Dec 2025 | 8,306,196 |
| Woodline Partners Lp | 31 Dec 2025 | 4,244,640 |
| Emerald Advisers, Llc | 31 Dec 2025 | 3,495,496 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 04 Feb 2026 | Announcement | Savara Announces Participation in Upcoming Investor Healthcare Conferences |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |